
Emanuela Zappulo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6061630/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Nasopharyngeal Microbiome Signature in COVID-19 Positive Patients: Can We Definitively Get a Role to Fusobacterium periodonticum?. Frontiers in Cellular and Infection Microbiology, 2021, 11, 625581.	3.9	59
2	The discovery of sofosbuvir: a revolution for therapy of chronic hepatitis C. Expert Opinion on Drug Discovery, 2015, 10, 1363-1377.	5.0	56
3	Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opinion on Drug Safety, 2018, 17, 709-717.	2.4	55
4	Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?. Expert Review of Anti-Infective Therapy, 2014, 12, 763-773.	4.4	41
5	Etiopathogenesis of autism spectrum disorders: Fitting the pieces of the puzzle together. Medical Hypotheses, 2013, 81, 26-35.	1.5	37
6	Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: Interim evaluations from the PITER network. PLoS ONE, 2017, 12, e0185728.	2.5	37
7	ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection. Current Medicinal Chemistry, 2014, 21, 3261-3270.	2.4	36
8	Discontinued drugs in 2012 – 2013: hepatitis C virus infection. Expert Opinion on Investigational Drugs, 2015, 24, 239-251.	4.1	35
9	MK-5172: a second-generation protease inhibitor for the treatment of hepatitis C virus infection. Expert Opinion on Investigational Drugs, 2014, 23, 719-728.	4.1	32
10	Prevention of mother-to-child transmission of hepatitis B virus and hepatitis C virus. Expert Review of Anti-Infective Therapy, 2014, 12, 775-782.	4.4	30
11	Real-World Efficacy and Safety of Pangenotypic Direct-Acting Antivirals Against Hepatitis C Virus Infection. Reviews on Recent Clinical Trials, 2019, 14, 173-182.	0.8	30
12	Asunaprevir, a protease inhibitor for the treatment of hepatitis C infection. Therapeutics and Clinical Risk Management, 2014, 10, 493.	2.0	29
13	Investigational nucleoside and nucleotide polymerase inhibitors and their use in treating hepatitis C virus. Expert Opinion on Investigational Drugs, 2014, 23, 1211-1223.	4.1	28
14	Efficacy and Safety of Sofosbuvir in the Treatment of Chronic Hepatitis C: The Dawn of a New Era. Reviews on Recent Clinical Trials, 2014, 9, 1-7.	0.8	26
15	Vitamin D deficiency is a risk factor for infections in patients affected by HCV-related liver cirrhosis. International Journal of Infectious Diseases, 2017, 63, 23-29.	3.3	26
16	Serum KL-6 Could Represent a Reliable Indicator of Unfavourable Outcome in Patients with COVID-19 Pneumonia. International Journal of Environmental Research and Public Health, 2021, 18, 2078.	2.6	24
17	Pneumocystis jirovecii Pneumonia in Non-HIV Patients Recovering from COVID-19: A Single-Center Experience. International Journal of Environmental Research and Public Health, 2021, 18, 11399.	2.6	24
18	<i>Pneumocystis jirovecii</i> pneumonia in an immunocompetent patient recovered from COVID-19. Infectious Diseases, 2021, 53, 382-385.	2.8	23

Emanuela Zappulo

#	Article	IF	CITATIONS
19	Incidence and Predictive Risk Factors of Infective Events in Patients With Multiple Sclerosis Treated With Agents Targeting CD20 and CD52 Surface Antigens. Open Forum Infectious Diseases, 2019, 6, ofz445.	0.9	21
20	Investigational direct-acting antivirals in hepatitis C treatment: the latest drugs in clinical development. Expert Opinion on Investigational Drugs, 2016, 25, 557-572.	4.1	19
21	Prevalence of SARS-CoV-2 Antibodies in Multiple Sclerosis: The Hidden Part of the Iceberg. Journal of Clinical Medicine, 2020, 9, 4066.	2.4	19
22	Use of Aspergillus fumigatus real-time PCR in bronchoalveolar lavage samples (BAL) for diagnosis of invasive aspergillosis, including azole-resistant cases, in high risk haematology patients: the need for a combined use with galactomannan. Medical Mycology, 2019, 57, 987-996.	0.7	18
23	Beclabuvir for the treatment of hepatitis C. Expert Opinion on Investigational Drugs, 2015, 24, 1111-1121.	4.1	17
24	Infections worsen prognosis of patients with cirrhosis irrespective of the liver disease stage. European Journal of Internal Medicine, 2017, 46, e45-e47.	2.2	16
25	Prevalence and risk factors of erectile dysfunction in patients with hepatitis B virus or hepatitis C virus or chronic liver disease: results from a prospective study. Sexual Health, 2018, 15, 408.	0.9	16
26	Severe Vitamin D Deficiency Increases Mortality Among Patients With Liver Cirrhosis Regardless of the Presence of HCC. In Vivo, 2019, 33, 177-182.	1.3	16
27	Prevalence of Congenital Cytomegalovirus Infection Assessed Through Viral Genome Detection in Dried Blood Spots in Children with Autism Spectrum Disorders. In Vivo, 2017, 31, 467-473.	1.3	16
28	Oral Vancomycin Prophylaxis for Primary and Secondary Prevention of Clostridioides difficile Infection in Patients Treated with Systemic Antibiotic Therapy: A Systematic Review, Meta-Analysis and Trial Sequential Analysis. Antibiotics, 2022, 11, 183.	3.7	16
29	Diagnostic Accuracy of PIVKA-II, Alpha-Fetoprotein and a Combination of both in Diagnosis of Hepatocellular Carcinoma in Patients Affected by Chronic HCV Infection. In Vivo, 2017, 31, 695-700.	1.3	15
30	The role of curcumin in liver diseases. Archives of Medical Science, 2019, 15, 1608-1620.	0.9	14
31	Bacterial and CMV pneumonia in a patient treated with alemtuzumab for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2019, 27, 44-45.	2.0	13
32	Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab. Infection, 2019, 47, 59-65.	4.7	12
33	Prevalence and titre of antibodies to cytomegalovirus and epstein-barr virus in patients with autism spectrum disorder. In Vivo, 2014, 28, 621-6.	1.3	11
34	GS-9669: a novel non-nucleoside inhibitor of viral polymerase for the treatment of hepatitis C virus infection. Expert Review of Anti-Infective Therapy, 2014, 12, 1179-1186.	4.4	10
35	COVID-19 prevention and multiple sclerosis management: The SAFE pathway for the post-peak. Multiple Sclerosis and Related Disorders, 2020, 44, 102282.	2.0	10
36	ls it possible to predict HCV-related liver cirrhosis non-invasively through routine laboratory parameters?. Infezioni in Medicina, 2014, 22, 11-8.	1.1	10

Emanuela Zappulo

#	Article	IF	CITATIONS
37	Management of chronic viral hepatitis in the hematological patient. Expert Review of Anti-Infective Therapy, 2018, 16, 227-241.	4.4	9
38	Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. Journal of Neurology, 2022, 269, 3301-3307.	3.6	9
39	Efficacy and safety of a fixed dose combination tablet of asunaprevir + beclabuvir + daclatasvir for the treatment of Hepatitis C. Expert Opinion on Pharmacotherapy, 2020, 21, 261-273.	1.8	8
40	Prevalence of herpes simplex virus 1 and 2 antibodies in patients with autism spectrum disorders. In Vivo, 2014, 28, 667-71.	1.3	8
41	Exposure to Varicella Zoster Virus is higher in children with autism spectrum disorder than in healthy controls. Results from a case-control study. In Vivo, 2014, 28, 627-31.	1.3	7
42	Asunaprevir for hepatitis C: a safety evaluation. Expert Opinion on Drug Safety, 2015, 14, 1631-1646.	2.4	6
43	Invasive pulmonary aspergillosis and pulmonary tuberculosis in a patient treated with infliximab for Crohn's disease. IDCases, 2019, 17, e00537.	0.9	6
44	The serum-ascites vitamin D gradient (SADG): A novel index in spontaneous bacterial peritonitis. Clinics and Research in Hepatology and Gastroenterology, 2019, 43, e57-e60.	1.5	6
45	Unsolved Issues in the Treatment of Spontaneous Peritonitis in Patients with Cirrhosis: Nosocomial Versus Community-acquired Infections and the Role of Fungi. Reviews on Recent Clinical Trials, 2019, 14, 129-135.	0.8	6
46	Prevalence of HHV-6 and HHV-8 antibodies in patients with autism spectrum disorders. In Vivo, 2013, 27, 843-9.	1.3	5
47	Hepatitis C screening in the Emergency Department of a large hospital in southern Italy: results of a pilot study. Infezioni in Medicina, 2019, 27, 32-39.	1.1	4
48	Update on infective complications in patients treated with alemtuzumab for multiple sclerosis: review and meta-analysis of real-world and randomized studies. Expert Opinion on Drug Safety, 2021, 20, 1237-1246.	2.4	3
49	Novel strategies for the management of bacterial and fungal infections in patients with liver cirrhosis: focus on new antimicrobials. Expert Review of Anti-Infective Therapy, 2020, 18, 191-202.	4.4	3
50	Epidemiological and clinical features of syphilis in the 21st century: A seven-year observational retrospective study of outpatients. Clinical Epidemiology and Global Health, 2022, 16, 101100.	1.9	3
51	Impact of an anti-infective screening and monitoring protocol together with infectious disease consultation in preventing infective adverse events in patients treated with anti-CD20/CD52 agents for multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 63, 103814.	2.0	2
52	Prevalence of HSV1/2 Congenital Infection Assessed Through Genome Detection on Dried Blood Spot in Individuals with Autism Spectrum Disorders. In Vivo, 2018, 32, 1255-1258.	1.3	1
53	Case Report: Discovery a Novel SARS-CoV-2 Variant in a Six-Months Long-Term Swab Positive Female Suffering From Non-Hodgkin Lymphoma. Frontiers in Oncology, 2021, 11, 705948.	2.8	1
54	Urinary polyomavirus infections in neurodevelopmental disorders. Open Journal of Psychiatry, 2013, 03, 18-25.	0.6	1

#	Article	IF	CITATIONS
55	Should SARS CoV-2 infection be considered an independent risk factor for Pneumocystis jirovecii pneumonia? Emerging data after two years of pandemic from a single center experience. Reviews on Recent Clinical Trials, 2022, 17, .	0.8	1
56	No evidence of congenital varicella zoster virus infection assessed through dried blood spot in children with autism spectrum disorders. Future Virology, 2017, 12, 333-337.	1.8	0